Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Trial to Evaluate the Efficacy and Safety of ASLAN004 in Adult Patients with Moderate-to-Severe Atopic Dermatitis (IRB 273816)


Collapse Overview 
Collapse sponsor award id
ASLAN004-003


Collapse Biography 

Collapse Time 
Collapse start date
2022-05-16

Collapse end date
2032-05-15